Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity. (29th June 2022)

• Record Type: Journal Article
• Authors: Henriksen, Peter A.; Hall, Peter; Oikonomidou, Olga; MacPherson, Iain R.; Maclean, Morag; Lewis, Steff; McVicars, Heather; Broom, Angus; Scott, Fiona; McKay, Pam; Borley, Annabel; Rowntree, Clare; Lord, Simon; Collins, Graham; Radford, John; Guppy, Amy; Payne, John R.; Newby, David E.; Mills, Nick L.; Lang, Ninian N.
• Is Part Of: Circulation. Volume 15:Number 7(2022)
• Page Start: e009445
• Publication Date: 2022-06-29
• Subjects: anthracyclines -- lymphoma -- magnetic resonance imaging -- troponin -- ventricular dysfunction; Heart failure -- Periodicals; 616.129005
• DOI: 10.1161/CIRCHEARTFAILURE.121.009445
• Languages: English
• ISSNs: 1941-3289

Abstract

Abstract : Background: Anthracyclines are effective cytotoxic drugs used in the treatment of breast cancer and lymphoma but are associated with myocardial injury, left ventricular dysfunction, and heart failure. Anthracycline-induced cardiotoxicity is highly variable in severity and without a proven therapeutic intervention. β-Adrenergic receptor blockers and renin-angiotensin-system inhibitor therapies have been associated with modest cardioprotective effects in unselected patients. Methods: The Cardiac CARE trial is a multicentre prospective randomized open-label blinded end point trial of combination β-adrenergic receptor blocker and renin-angiotensin-system inhibitor therapy in patients with breast cancer and non-Hodgkin lymphoma receiving anthracycline chemotherapy that is associated with myocardial injury. Patients at higher risk of cardiotoxicity with plasma high-sensitivity cTnI (cardiac troponin I) concentrations in the upper tertile at the end of chemotherapy are randomized to standard of care plus combination candesartan and carvedilol therapy or standard of care alone. All patients undergo cardiac magnetic resonance imaging before and 6 months after anthracycline treatment. The primary end point is the change in left ventricular ejection fraction at 6 months after chemotherapy. In low-risk nonrandomized patients, left ventricular ejection fraction before and 6 months after anthracycline will be compared with define the specificity of the high-sensitivity cTnI assay for identifying low-risk participants who do not develop left ventricular systolic dysfunction. Discussion: Cardiac CARE will examine whether cardiac biomarker monitoring identifies patients at risk of left ventricular dysfunction following anthracycline chemotherapy and whether troponin-guided treatment with combination candesartan and carvedilol therapy prevents the development of left ventricular dysfunction in these high-risk patients.